CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.

16 June 2025, 14:00 CEST / 8:00 AM ET

Register and attend

Bo Håkansson increases ownership in Hansa Medical AB (publ) through acquisition of more than 1 million shares

23 Jun 2011, 08:30
Regulatory information

Bo Håkansson has acquired 1,038,609 shares in Hansa Medical AB (publ) through his fully owned company Farstorp Invest AB. The acquisition corresponds to approximately 8 % of votes and capital in Hansa Medical. Following the acquisition and the recently accomplished rights issue, Bo Håkansson via company holds 53,6% of votes and capital in Hansa Medical.

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77
E-mail: [email protected]

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.